Free Trial
OTCMKTS:EMMA

Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

Emmaus Life Sciences logo
$0.02 0.00 (0.00%)
As of 03/28/2025

About Emmaus Life Sciences Stock (OTCMKTS:EMMA)

Key Stats

Today's Range
$0.0189
$0.0189
50-Day Range
$0.01
$0.05
52-Week Range
$0.00
$0.13
Volume
N/A
Average Volume
46,913 shs
Market Capitalization
$1.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Remove Ads

Emmaus Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

EMMA MarketRank™: 

Emmaus Life Sciences scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Emmaus Life Sciences.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Emmaus Life Sciences is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Emmaus Life Sciences is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.02% of the float of Emmaus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Emmaus Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Emmaus Life Sciences has recently increased by 30.61%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Emmaus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Emmaus Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.02% of the float of Emmaus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Emmaus Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Emmaus Life Sciences has recently increased by 30.61%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Emmaus Life Sciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Emmaus Life Sciences this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for EMMA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.42% of the stock of Emmaus Life Sciences is held by institutions.

  • Read more about Emmaus Life Sciences' insider trading history.
Receive EMMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

EMMA Stock News Headlines

The Dirty Secret About Gold Mining Stocks...
Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.
Emmaus Life Sciences appoints new board member
See More Headlines

EMMA Stock Analysis - Frequently Asked Questions

Emmaus Life Sciences' stock was trading at $0.0085 at the beginning of 2025. Since then, EMMA shares have increased by 122.4% and is now trading at $0.0189.
View the best growth stocks for 2025 here
.

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX).

Company Calendar

Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:EMMA
Employees
60
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$29.60 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
41,513,000
Market Cap
$1.21 million
Optionable
Not Optionable
Beta
6.47
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (OTCMKTS:EMMA) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners